Cannabix Technologies Announces Detection of Fentanyl in Human Breath

Vancouver, British Columbia, November 9, 2026 -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana, multi-drug, and alcohol breath testing technologies announces detection of fentanyl in human breath samples collected using the Cannabix Breath Collection Unit (“BCU”) and Breath Cartridge technology and analyzed by Omega Laboratories Inc. ("Omega") utilizing liquid chromatography-mass spectrometry ("LC-MS").

Fentanyl Detection in Breath Represents a Significant Scientific and Commercial Milestone

Fentanyl is illegal and is a highly potent synthetic opioid associated with a growing public health and workplace safety crisis across North America. The identification of fentanyl in human breath demonstrates the ability of the standardized Cannabix Breath Collection Unit ("BCU"), disposable Breath Cartridges, and associated laboratory-developed analytical methods, to capture and preserve measurable quantities of fentanyl from exhaled breath from a drug user (Figure 1 and 2). Human breath contains fentanyl at trace concentrations that are substantially lower than those typically measured in urine, oral fluid, or blood, making reliable detection dependent on highly sensitive breath collection and analytical technologies.

These findings represent an important milestone in the evolution of the Cannabix BCU platform from a THC-focused technology toward a broader multi-panel breath testing platform. The results reinforce the Company's ongoing breath-based detection capabilities for multiple classes of drugs, including opioids, stimulants, and other drugs of abuse, addressing applications in workplace safety, transportation, substance-use disorder programs, pain management monitoring, forensic testing, and law enforcement. The multidrug collection capability is available with the current BCU and Multi-Drug Breath Cartridges.

"The detection of fentanyl in human breath represents a significant milestone. Compared to traditional biological samples like urine, oral fluid, or blood, human breath contains extremely low levels of fentanyl compounds. Making collection and confirmation extremely challenging. There is very limited historical research demonstrating fentanyl detection in breath, which makes these findings particularly encouraging. We believe these results further demonstrate the versatility of our technology and its applicability beyond cannabis into broader multi-drug breath testing markets.", stated Rav Mlait, CEO of Cannabix Technologies Inc.